相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
Josef S. Smolen et al.
LANCET (2019)
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response
Roy M. Fleischmann et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial
Roy Fleischmann et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM
Bruno Fautrel et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT
Vibeke Strand et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs
Vibeke Strand et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial
Vibeke Strand et al.
RMD OPEN (2019)
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
Mark C. Genovese et al.
LANCET (2018)
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial
Gerd R. Burmester et al.
LANCET (2018)
Diagnosis and Management of Rheumatoid Arthritis A Review
Daniel Aletaha et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes
Mark Genovese et al.
ARTHRITIS RESEARCH & THERAPY (2018)
The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission
Lilian H. D. van Tuyl et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Peter C. Taylor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study
Edward C. Keystone et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Jasvinder A. Singh et al.
ARTHRITIS CARE & RESEARCH (2016)
A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective
Peter C. Taylor et al.
RHEUMATOLOGY INTERNATIONAL (2016)
Patient-Reported Outcomes From a Two-Year Head-to-Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis
Roy Fleischmann et al.
ARTHRITIS CARE & RESEARCH (2016)
Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs
Vibeke Strand et al.
ARTHRITIS RESEARCH & THERAPY (2015)
Stiffness is more than just duration and severity: a qualitative exploration in people with rheumatoid arthritis
Serena Halls et al.
RHEUMATOLOGY (2015)
AB0266 Responsiveness and minimal important difference of the rheumatoid arthritis-work instability scale (ra-wis)
D. Revicki et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Stiffness Has Different Meanings, I Think, to Everyone: Examining Stiffness From the Perspective of People Living With Rheumatoid Arthritis
Ana-Maria Orbai et al.
ARTHRITIS CARE & RESEARCH (2014)
It's Good to Feel Better But It's Better To Feel Good and Even Better to Feel Good as Soon as Possible for as Long as Possible. Response Criteria and the Importance of Change at OMERACT 10
Vibeke Strand et al.
JOURNAL OF RHEUMATOLOGY (2011)
Adult measures of general health and health-related quality of life: Medical Outcomes Study Short Form 36-Item (SF-36) and Short Form 12-Item (SF-12) Health Surveys, Nottingham Health Profile (NHP), Sickness Impact Profile (SIP), Medical Outcomes Study Sh
Lucy Busija et al.
ARTHRITIS CARE & RESEARCH (2011)
What Outcomes From Pharmacologic Treatments Are Important to People With Rheumatoid Arthritis? Creating the Basis of a Patient Core Set
T. Sanderson et al.
ARTHRITIS CARE & RESEARCH (2010)
Use of spydergrams to present and interpret SF-36 health-related quality of life data across rheumatic diseases
V. Strand et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Predicting Depression in Rheumatoid Arthritis: The Signal Importance of Pain Extent and Fatigue, and Comorbidity
Frederick Wolfe et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)
Morning stiffness and its influence on early retirement in patients with recent onset rheumatoid arthritis
G. Westhoff et al.
RHEUMATOLOGY (2008)
Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis
G. Wells et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Problems faced at work due to inflammatory arthritis: New insights gained from understanding patients' perspective
Diane Lacaille et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2007)
Fatigue in rheumatoid arthritis reflects pain, not disease activity
L. C. Pollard et al.
RHEUMATOLOGY (2006)
Patients' perceptions of fatigue in rheumatoid arthritis: Overwhelming, uncontrollable, ignored
S Hewlett et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2005)
Normative values for the health assessment questionnaire disability index -: Benchmarking disability in the general population
E Krishnan et al.
ARTHRITIS AND RHEUMATISM (2004)
Preferences for improved health examined in 1,024 patients with rheumatoid arthritis: Pain has highest priority
T Heiberg et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2002)
分享论文
